Wilson's Disease clinical trials at UC Davis
2 research studies open to eligible people
open to eligible people ages 18 years and up
The main objective of the study is to evaluate the change in liver copper (Cu) concentration following 48 weeks of treatment with ALXN1840 in adult participants with Wilson Disease (WD) who have been previously treated for at least 1 year with standard of care (that is, trientine, penicillamine, or zinc). In the Treatment Period, efficacy and safety of ALXN1840 will be assessed at Week 48.
Sacramento, California and other locations
Effectiveness and Safety of Experimental ALXN1840 Versus Standard of Care for Wilson Disease (copper buildup)
open to eligible people ages 12 years and up
The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD) participants aged 12 and older in the Primary Evaluation Period. In addition, efficacy and safety will be evaluated during an optional 60-month Extension Period.
Los Angeles, California and other locations